Latest News and Press Releases
Want to stay updated on the latest news?
-
June 15, 2018Announcement no. 11 In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of...
-
May 3, 2018Announcement no. 10 Important milestones in global roll-out of The NGAL Test™ secured in first quarter 2018 In the first quarter of 2018, BioPorto secured...
-
April 18, 2018Announcement no. 9 Ole Larsen, Executive Vice President & CFO of Bavarian Nordic, will as of June 1, 2018, join BioPorto as the new Chief Financial Officer. In 2008, Ole Larsen...
-
April 13, 2018Announcement no. 8 BioPorto A/S held its Annual General Meeting today where the shareholders approved the report on the Company’s activities and adopted the 2017 Annual Report. In...
-
April 3, 2018Announcement no. 7 BioPorto receives intention to grant for a divisional NGAL cutoff patent in Europe The European Patent Office has published intention to grant BioPorto’s patent no....
-
21. marts 2018 Meddelelses nummer: 6 Indkaldelse til ordinær generalforsamling Bestyrelsen indkalder herved til ordinær generalforsamling i BioPorto A/S: Den 13. april 2018, kl. 15.00 På...
-
March 21, 2018 Announcement no. 6 ...
-
BioPorto har i 2017 fokuseret på at skabe vækst og sikre en målrettet eksekvering af topprioriteterne på den strategiske agenda; at styrke opmærksomheden om anvendelse af Neutrophil Gelatinase...
-
In 2017, BioPorto remained focused on creating growth and ensuring tight execution of the top priorities in our strategic agenda; increasing awareness about the use of Neutrophil Gelatinase Associated...
-
BioPorto has enrolled the last patient today in the clinical study that will generate data for BioPorto’s FDA application for The NGAL Test™ in the US. Patient enrolment had been slightly extended...